Skip to content

Annexon ANNX Net Investment in Lease

Net Investment in Lease at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
Omeros logo
OmerosOMER
Vor Biopharma logo
Vor BiopharmaVOR
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX

Segments

By geography

See full
Brisbane California$14.8M-9.2%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's net investment in lease?
Annexon (ANNX) reported net investment in lease of $14.77M in Q1 2026.
How has Annexon's net investment in lease changed year-over-year?
Annexon's net investment in lease decreased by 9.7% year-over-year, from $16.35M to $14.77M.
What is the long-term trend for Annexon's net investment in lease?
Over 4 years (2021 to 2025), Annexon's net investment in lease has grown at a -7.0% compound annual growth rate (CAGR), from $20.33M to $15.19M.